NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations
About Mitsubishi Tanabe Pharma Corporation and Mitsubishi Chemical Group
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future." With the MISSION of "creating hope for all facing illness," MTPC is prioritizing work on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety, focusing on the disease areas of central nervous system and immuno-inflammation. For more information, go to https://www.mt-pharma.co.jp/e/.
About Mitsubishi Tanabe Pharma GmbH
Mitsubishi Tanabe Pharma GmbH, based in Düsseldorf, was founded in 2003 under the name Mitsubishi Pharma Deutschland GmbH as a subsidiary of Mitsubishi Pharma Europe Ltd. (London/UK) which is an affiliate of Mitsubishi Tanabe Pharma Cooperation in Japan. Germany was the first country representative to market products from its own research outside Asia.
ReferencesData on File. S Fahn. Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl.2006;(71):1-15. doi: 10.1007/978-3-211-33328-0_1.Dijk JM et al, The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When? J Parkinsons Dis 2020;10(s1):S65-S73.?Efficacy, Safety and Tolerability Study of ND0612 vs. Oral IR-LD/CD in Subjects with PD Experiencing Motor Fluctuations (BouNDless). Available at: https://clinicaltrials.gov/ct2/show/NCT04006210. Accessed November 7, 2022.S Isaacson, C Warren Olanow, T Simuni, et al. Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Results from the ongoing BeyoND study. Poster presented at: American Academy of Neurology Annual Meeting; 2022 Apr 2-7; Seattle, WA.Who Has Parkinson's? Parkinson's Foundation. Available at: https://www.parkinson.org/Understanding-Parkinsons/Statistics#:~:text=More%20than%2010%20million%20people. Accessed November 10, 2022.Parkinson's 101. The Michael J. Fox Foundation. Available at: https://www.michaeljfox.org/parkinsons-101#q2. Accessed March 15, 2022. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE.
Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013.Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee.International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-1266.C Warren Olanow, J Obeso, F Stocchi. Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease.?Nat Rev Neurol?2, 382–392 (2006).
Name: Enola Chen
View original content:https://www.prnewswire.co.uk/news-releases/neuroderm-announces-highly-positive-results-from-the-pivotal-phase-iii-boundless-trial-evaluating-nd0612-in-parkinsons-disease-patients-with-motor-fluctuations-301715873.html